Shikai Geng

Jiang Yue Road 2000
Shanghai, 201112, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.

Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.

Journal: Acta biochimica et biophysica Sinica
Published: September 02, 2025

Carbon ion combined photon radiotherapy induces ferroptosis via NCOA4-mediated ferritinophagy in glioblastoma.

Carbon ion combined photon radiotherapy induces ferroptosis via NCOA4-mediated ferritinophagy in glioblastoma.

Journal: Redox biology
Published: July 16, 2025

Inhibition of DDR1 potentiates carbon ion radiotherapy by promoting ferroptosis and immunogenic death in head and neck squamous cell carcinoma.

Inhibition of DDR1 potentiates carbon ion radiotherapy by promoting ferroptosis and immunogenic death in head and neck squamous cell carcinoma.

Journal: Journal of translational medicine
Published: June 15, 2025

Triptonide Mediates Apoptosis and Autophagy via ROS/p38 MAPK Activation and mTOR/NF-κB Inhibition in Nasopharyngeal Carcinoma: Insights from Network Pharmacology, Molecular Docking, and Experimental Validation.

Triptonide Mediates Apoptosis and Autophagy via ROS/p38 MAPK Activation and mTOR/NF-κB Inhibition in Nasopharyngeal Carcinoma: Insights from Network Pharmacology, Molecular Docking, and Experimental Validation.

Journal: Current pharmaceutical design
Published: March 08, 2025

Exploring the Therapeutic Potential of Triptonide in Salivary Adenoid Cystic Carcinoma: A Comprehensive Approach Involving Network Pharmacology and Experimental Validation.

Exploring the Therapeutic Potential of Triptonide in Salivary Adenoid Cystic Carcinoma: A Comprehensive Approach Involving Network Pharmacology and Experimental Validation.

Journal: Current pharmaceutical design
Published: March 23, 2024

Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.

Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.

Journal: Clinical rheumatology
Published: August 09, 2023

TRIB3 promotes malignancy of head and neck squamous cell carcinoma via inhibiting ferroptosis.

TRIB3 promotes malignancy of head and neck squamous cell carcinoma via inhibiting ferroptosis.

Journal: Cell death & disease
Published: August 09, 2023

The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.

The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.

Journal: Clinical rheumatology
Published: March 07, 2023

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation.

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation.

Journal: Nature communications
Published: May 19, 2022

Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study.

Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study.

Journal: Lupus science & medicine
Published: May 02, 2022

Mesenchymal Stem Cells Inhibits Migration and Vasculogenic Mimicry in Nasopharyngeal Carcinoma Via Exosomal MiR-125a.

Mesenchymal Stem Cells Inhibits Migration and Vasculogenic Mimicry in Nasopharyngeal Carcinoma Via Exosomal MiR-125a.

Journal: Frontiers in oncology
Published: September 23, 2021

Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.

Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.

Journal: Clinical and experimental rheumatology
Published: July 02, 2021
Showing 1-12 of 19

Last Updated: 09/26/2026